Online citations, reference lists, and bibliographies.
← Back to Search

Estimation Of Future Mortality From Pleural Malignant Mesothelioma In Japan Based On An Age-cohort Model.

Takehiko Murayama, K. Takahashi, Yuji Natori, N. Kurumatani
Published 2006 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Japanese consumption of asbestos increased rapidly after the 1950s and lingered at a high level while the world's consumption decreased substantially after the 1980s. Mesothelioma is due primarily to asbestos, and the number of deaths in Japan is expected to increase in the future. METHOD We estimated the future number of pleural mesothelioma deaths among males in Japan using an age-cohort model. RESULTS Analyses showed that there would be about 100,000 deaths in Japan due to pleural mesothelioma in the next 40 years. Compared with the statistics in European countries, the ratio of expected death numbers to the population size is remarkably close to linear. The data-point for Japan was slightly lower than that which could be expected from the linear relationship. CONCLUSIONS The limited availability of data may result in underestimation. Taking into consideration the consumption pattern of asbestos in recent decades, the incorporation of later cohorts will improve the estimation.
This paper references



This paper is referenced by
10.1038/mt.2011.305
BioKnife, a uPA activity-dependent oncolytic Sendai virus, eliminates pleural spread of malignant mesothelioma via simultaneous stimulation of uPA expression.
Y. Morodomi (2012)
10.1265/JJH.66.543
科学技術振興調整費「アスベスト関連疾患への総括的取り組み」班研究:成果報告
剛巳 大槻 (2011)
10.2482/HAIGAN.49.248
Outcome of Extrapleural Pneumonectomy for Malignant Pleural Mesothelioma
Toshikazu Yusa (2009)
10.1053/J.SEMDP.2006.06.004
Pathological recognition of diffuse malignant mesothelioma of the pleura: the significance of the historical perspective as regards this signal tumor.
E. Mark (2006)
Overexpression of SOCS 3 exhibits preclinical antitumor activity against malignant pleural mesothelioma
K. Iwahori (2010)
Aminopeptidase N / CD 13 as a Potential Therapeutic Target in Malignant Pleural Mesothelioma
T. Otsuki (2018)
10.1539/sangyoeisei.e8004
Asbestos Clinics and Asbestos Health Examinations
Norihisa Nagao (2008)
10.3892/mmr_00000081
Activation of the PI3K-AKT pathway in human malignant mesothelioma cells.
Y. Suzuki (2009)
10.1179/oeh.2007.13.4.398
Incidence and Descriptive Epidemiology of Mesothelioma in the United States, 1999–2002
Theodore C. Larson (2007)
10.1265/JJH.67.5
[A comprehensive review of literature to investigate development of global knowledge and consensus on asbestos carcinogenicity: up to the report and recommendations by UICC Working Group in 1964].
Norio Kurumatani (2012)
10.1038/onc.2009.415
A novel translational approach for human malignant pleural mesothelioma: heparanase-assisted dual virotherapy
Y. Watanabe (2010)
10.1016/j.prp.2016.12.025
Malignant peritoneal mesothelioma, clear cell variant, in a female and its differentiation from clear cell carcinoma.
H. Hayashi (2017)
10.1016/j.lungcan.2008.02.012
Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
K. Iwahori (2008)
Asbestos exposure and malignant mesothelioma in Korea.
K. Lee (2009)
10.1002/ijc.27611
SOCS‐1 gene delivery cooperates with cisplatin plus pemetrexed to exhibit preclinical antitumor activity against malignant pleural mesothelioma
K. Iwahori (2013)
10.1016/j.lungcan.2009.01.011
Accuracy of pathological diagnosis of mesothelioma cases in Japan: clinicopathological analysis of 382 cases.
Y. Takeshima (2009)
10.4137/CCRPM.S577
Immunological Changes in Mesothelioma Patients and Their Experimental Detection
M. Maeda (2008)
10.1186/s12885-019-5591-7
Physician requests by patients with malignant pleural mesothelioma in Japan
Yasuko Nagamatsu (2019)
10.1165/rcmb.2010-0213OC
Reduction of CXC chemokine receptor 3 in an in vitro model of continuous exposure to asbestos in a human T-cell line, MT-2.
M. Maeda (2011)
10.4049/jimmunol.1300448
A Novel Targeting Therapy of Malignant Mesothelioma Using Anti-Podoplanin Antibody
S. Abe (2013)
10.1007/s00280-010-1503-x
The therapeutic efficacy of S-1 against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice
Trung The Van (2010)
10.1002/ajim.20743
Asbestos fiber concentration in the area surrounding a former asbestos cement plant and excess mesothelioma deaths in residents.
S. Kumagai (2009)
10.1016/j.taap.2010.09.026
Effectiveness of serum megakaryocyte potentiating factor in evaluating the effects of chrysotile and its heated products on respiratory organs.
Ayako Takata (2011)
10.1146/annurev-publhealth-031811-124704
The worldwide pandemic of asbestos-related diseases.
L. Stayner (2013)
10.1183/13993003.01610-2017
Aminopeptidase N/CD13 as a potential therapeutic target in malignant pleural mesothelioma
T. Otsuki (2018)
10.5772/intechopen.90763
Suppressed Immune System Caused by Exposure to Asbestos and Malignant Mesothelioma
Y. Nishimura (2020)
10.1002/jmri.22372
Imaging of the pleura
E. J. Helm (2010)
10.1186/1471-2458-12-314
Mesothelioma incidence surveillance systems and claims for workers’ compensation. Epidemiological evidence and prospects for an integrated framework
A. Marinaccio (2012)
10.1289/ehp.1002845
Global Magnitude of Reported and Unreported Mesothelioma
Eun-Kee Park (2011)
10.1007/s12199-007-0015-8
Molecular biology of malignant mesothelioma
Y. Sekido (2008)
10.1309/AJCPT94JVWIHBKRD
Diagnostic usefulness of p16/CDKN2A FISH in distinguishing between sarcomatoid mesothelioma and fibrous pleuritis.
D. Wu (2013)
10.1093/carcin/bgp097
Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
K. Kawaguchi (2009)
See more
Semantic Scholar Logo Some data provided by SemanticScholar